Compare Novartis AG (NVS) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Verisign, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Verisign, Inc. trades at $277.5 (market cap $25.26B). The key difference: Novartis AG is far larger — about 11.5× Verisign, Inc.'s market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | VRSN | |
|---|---|---|
Market Cap | $290.25B | $25.26B |
Sector | Health | Technology |
52-Week High | $168.62 | $310.00 |
52-Week Low | $113.50 | $211.49 |
Enterprise Value | $330.27B | $26.50B |
Dividend Yield | 3.17% | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
